Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Assesment of patient competence in psychiatry: an overview of recent instruments].

Tijdschrift voor psychiatrie·2026

Same author

Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD).

Metabolomics : Official journal of the Metabolomic Society·2025

Same author

[The usefulness of therapeutic drug monitoring during treatment with second-generation antidepressants].

Tijdschrift voor psychiatrie·2025

Same author

[Neuropsychiatric associations in Belgium: from foundation to separation (1869-2008)].

Tijdschrift voor psychiatrie·2024

Same author

[Sustainability in Flemish and Dutch mental health care].

Tijdschrift voor psychiatrie·2023

Same author

Euthanasia of a person with a psychiatric disorder does not violate the European Convention on Human Rights (<i>Mortier v. Belgium</i> [no. 78017/17]).

European psychiatry : the journal of the Association of European Psychiatrists·2022

Search research articles

Related Experiment Videos

[Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics].

A De Nayer¹, M De Hert, A Scheen

¹Hôpital Sainte-Thérèse, B-6061 Montignies-sur-Sambres.

|August 7, 2007

Summary

Schizophrenia patients have a higher risk of type 2 diabetes, exacerbated by antipsychotic medications. Monitoring metabolic health is crucial due to these risks.

Related Experiment Videos

Area of Science:

Psychiatry and Endocrinology
Metabolic Syndrome Research
Pharmacovigilance of Antipsychotics

Background:

Schizophrenia and bipolar disorders are linked to increased type 2 diabetes prevalence.
Diabetes mellitus often remains undiagnosed in psychiatric patients due to silent symptoms and inadequate screening.
Schizophrenia itself may increase diabetes risk through lifestyle factors.

Framework:

Antipsychotic drug treatment, particularly second-generation antipsychotics (SGA), elevates diabetes risk.
Existing literature, though often retrospective, details adverse metabolic effects of SGAs, including glucose dysregulation and new-onset diabetes.
Risk varies among SGAs, with clozapine and olanzapine posing the highest risk, while amisulpride, aripiprazole, and ziprasidone appear safer.

Implementation:

Assessing the prevalence and risk factors of type 2 diabetes in schizophrenia patients.
Evaluating the metabolic side effects of various antipsychotic medications.
Comparing the diabetogenic potential and weight gain liability across different antipsychotics.

Implications:

Increased focus on physical health monitoring for individuals with mental health disorders.
Development of clinical guidelines for managing metabolic risks associated with antipsychotic use.
Need for prospective studies to confirm the association between specific SGAs and metabolic disturbances.